<a href="https://laohu8.com/S/TOVX">Theriva Biologics</a> Announces Corporate Reorganization, Cuts Workforce by 32% to Focus on Clinical Trials and Licensing Activities
**Theriva Biologics Announces Corporate Reorganization and Workforce Reduction** Theriva Biologics Inc. has announced a significant corporate reorganization aimed at focusing its efforts on business development, licensing activities, and advancing clinical trials for its lead product candidate, VCN-01. As part of the restructuring plan approved by the Board of Directors on September 28, 2025, the company implemented a workforce reduction of approximately 32%, affecting about seven employees. The move is expected to save Theriva around $2 million annually in compensation and benefits, with total restructuring charges estimated at $520,000 to be incurred in the fourth quarter of 2025. The company believes these changes will extend its cash runway into the second quarter of 2026 and better position it for upcoming regulatory meetings and planned clinical trials in pancreatic cancer and retinoblastoma.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-096047), on October 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.